Therapeutic Plasma Exchange (TPE) Response in Thrombotic Thrombocytopenic Purpura (TTP): A Case Report

Jony Santoso, Septian Adi Permana

Abstract

Background: Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy. It derives from a severe deficiency of disintegrin-like metalloproteinase with thrombospondin motif type 1 member 13-regulates (ADAMTS13). This case report aims to describe how therapeutic plasma exchange (TPE) with steroids can improve good clinical outcomes in TTP.

Case Illustration: A 72-year-old male presented to the emergency department with complaints of fever persisting for 1 week. The patient also complained of a productive cough and shortness of breath. Patient was found apathetic (E3M6V4) and fever (38.1°C). Other vital signs were normal. Thorax examination revealed minimal bilateral basal crackles. Minimal pitting-edema was found in both lower extremities. Patient underwent complete blood count that indicates leukocytosis (shift to the left), thrombocytopenia, hypoalbuminemia, and impaired renal function tests. Chest X-Ray revealed pulmonary edema in both lungs and infiltrates with air-bronchogram in the right paracardiac area. Diagnosis of TTP was established based on history and physical examinations related to TTP pentad criteria (fever, thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, and impaired renal function tests). Patient was then treated with TPE and steroids. Symptomatic treatments for the patient's complaints were given. Patient was then discharged from hospital after treatments.
Conclusion: This study provides a review of the expected course of treatment for patients with TTP. Treatment using TPE and steroids can increase platelet counts resulting in significant clinical improvements.

Keywords

Steroids; Therapeutic Plasma Exchange; Thrombotic Thrombocytopenic Purpura.

Full Text:

PDF

References

1. Sukumar S, Lämmle B, Cataland SR. Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. Journal of Clinical Medicine. 2021 Feb 2;10(3):536. doi:10.3390/jcm10030536
2. Paydary K, Banwell E, Tong J, Chen Y, Cuker A. Diagnostic accuracy of the plasmic score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta‐analysis. Transfusion. 2020 Aug 5;60(9):2047–57. doi:10.1111/trf.15954
3. Gogia P, Gbujie E, Benge E, Bhasin S. Thrombotic thrombocytopenic purpura: Revisiting a miss and an inevitable consequence. Cureus. 2020 Jul 19; doi:10.7759/cureus.9283
4. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2020 Oct;18(10):2503–12. doi:10.1111/jth.15009
5. Cugno M, Mancini I, Consonni D, De Zan V, Ardissino G, Griffini S, et al. Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2023 Mar 6; doi:10.1182/blood.2022018644
6. Najar H, Tuider L, Kukkar V, Quasem M. Thrombotic thrombocytopenic purpura: A rare cause of severe acute kidney injury. Cureus. 2022 Apr 17; doi:10.7759/cureus.24221
7. Filatov A, Kassar E, Cole O. Thrombotic thrombocytopenic purpura masquerading as acute ischemic stroke. Cureus. 2020 Apr 13; doi:10.7759/cureus.7661
8. Singh K, Kwong AC, Madarati H, Kunasekaran S, Sparring T, Fox-Robichaud AE, et al. Characterization of ADAMTS13 and von Willebrand factor levels in septic and non-septic ICU patients. PLOS ONE. 2021 Feb 19;16(2). doi:10.1371/journal.pone.0247017
9. Nicolotti D, Bignami EG, Rossi S, Vezzani A. A case of thrombotic thrombocytopenic purpura associated with covid-19. Journal of Thrombosis and Thrombolysis. 2021 Jan 3;52(2):468–70. doi:10.1007/s11239-020-02362-7
10. Watanabe H, Yamana H, Okada A, Matsui H, Fushimi K, Yasunaga H. Therapeutic plasma exchange for anti-glomerular basement membrane disease with dialysis-dependent kidney failure without diffuse alveolar hemorrhage. Journal of Nephrology. 2023 Jun 24;36(8):2317–25. doi:10.1007/s40620-023-01695-9
11. Matsumoto H, Takeba J, Umakoshi K, Kikuchi S, Ohshita M, Annen S, et al. ADAMTS13 activity decreases in the early phase of trauma associated with coagulopathy and systemic inflammation: A prospective observational study. Thrombosis Journal. 2021 Mar 12;19(1). doi:10.1186/s12959-021-00270-1
12. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2020 Oct;18(10):2496–502. doi:10.1111/jth.15010
13. Pan Z, Zhang Z, Yang Y, Hao W. The efficacy and safety of plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Journal of Healthcare Engineering. 2022 Mar 31;2022:1–6. doi:10.1155/2022/3519937
14. Lemiale V, Valade S, Mariotte E. Unresponsive thrombotic thrombocytopenic purpura (TTP): Challenges and solutions. Therapeutics and Clinical Risk Management. 2021 Jun;Volume 17:577–87. doi:10.2147/tcrm.s205632
15. Cilla N, Dallemagne J, Vanhove M, Stordeur P, Motte S, De Wilde V. Delayed thrombotic complications in a thrombotic thrombocytopenic purpura patient treated with caplacizumab. Journal of Hematology. 2020;9(3):84–8. doi:10.14740/jh614

DOI: https://doi.org/10.20961/soja.v5i1.91331

Refbacks

  • There are currently no refbacks.